NRAS and lung carcinoma: Importantly, NOP56 KD sensitized KRAS-mutant lung (A549), colon (HCT-116, DLD-1, and LS174T), pancreatic (MIAPaCa, HPAF-II) and primary KRAS-mutant lung cancer cells (PF563, PF139) to rapamycin, as well as NRAS-mutant lung cancer H1299 cells but not KRAS-wild-type H2405 (BRAF-mutant), EBC-1 (EGFR-mutant), H1993 (MET amplification) and H520 (FGFR1 amplification) cells (Fig. S3H, I).